Tobacco carcinogenesis: Mechanisms and biomarkers

Tobacco: Science, Policy and Public Health

Volumn , Issue , 2010, Pages

  Hecht, Stephen S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Biomarkers; Cancer; Cigarette smoke; Tobacco carcinogens; Tobacco smoke; Tumour induction

Indexed keywords

EID: 84866144884     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780199566655.003.0007     Document Type: Chapter

References (146)

1. Hecht, S.S. (1999). Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst, 91:1194-1210.
2. Hecht, S.S. (2003). Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. Nature Rev Cancer, 3:733-744.
3. Ding, L., Getz, G., Wheeler, D.A., Mardis, E.R., McLellan, M.D., Cibulskis, K. et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 455(7216):1069-1075.
4. Thorgeirsson, T.E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K.P. et al. (2008). A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature, 452(7187):638-642.
5. Hung, R.J., McKay, J.D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D. et al. (2008). A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature, 452(7187):633-637.
6. Amos, C.I., Wu, X., Broderick, P., Gorlov, I.P., Gu, J., Eisen, T. et al. (2008). Genomewide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet, 40:616-622.
7. Le Marchand, L., Derby, K.S., Murphy, S.E., Hecht, S.S., Hatsukami, D., Carmella, S.G. et al. (2008). Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res, 68(22):9137-9140.
8. Guengerich, F.P. (2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol, 14:611-650.
9. Jalas, J., Hecht, S.S., Murphy, S.E. (2005). Cytochrome P450 2A enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen. Chem Res Toxicol, 18:95-110.
10. Zhang, L., Lee, J.J., Tang, H., Fan, Y.-H., Xiao, L., Ren, H. et al. (2008). Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. Cancer Prev Res, 1:112-118.
11. Gümüs, Z.H., Du, B., Kacker, A., Boyle, J.O., Bocker, J.M., Mukherjee, P. et al. (2008). Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia. Cancer Prev Res, 1:100-111.
12. Nebert, D.W., Dalton, T.P., Okey, A.B., and Gonzalez, F.J. (2004). Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem, 279(23):23847-23850.
13. Quinn, A.M., Harvey, R.G., and Penning, T.M. (2008). Oxidation of PAH transdihydrodiols by human aldo-keto reductase AKR1B10. Chem Res Toxicol, 21:2207-2215.
14. Armstrong, R.N. (1997). Glutathione-S-transferases. In: F.P. Guengerich, editor. Comprehensive Toxicology: Biotransformation. New York: Elsevier Science, 307-327.
15. Burchell, B., McGurk, K., Brierley, C.H., and Clarke, D.J. (1997). UDPGlucuronosyltransferases. In: Guengerich FP, editor. Comprehensive Toxicology:Biotransformation. New York: Elsevier Science, 401-436.
16. Vineis, P., Veglia, F., Benhamou, S., Butkiewicz, D., Cascorbi, I., Clapper, M.L. et al. (2003). CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer, 104(5):650-657.
17. International Agency for Research on Cancer (2004). Tobacco Smoke and Involuntary Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, FR: IARC, 1179-1187.
18. Veglia, F., Loft, S., Matullo, G., Peluso, M., Munnia, A., Perera, F., et al. (2008). DNA adducts and cancer risk in prospective studies: a pooled analysis and a meta-analysis. Carcinogenesis, 29(5):932-936.
19. Liu, G., Zhou, W., and Christiani, D.C. (2005). Molecular epidemiology of non-small cell lung cancer. Semin Respir Crit Care Med, 26(3):265-272.
20. Delaney, J.C. and Essigmann, J.M. (2008). Biological properties of single chemical-DNA adducts: a twenty year perspective. Chem Res Toxicol, 21(1):232-252.
21. Pfeifer, G.P., Denissenko, M.F., Olivier, M., Tretyakova, N., Hecht, S.S., and Hainaut, P. (2002). Tobacco smoke carcinogens, DNA damage and p53 mutations in smokingassociated cancers. Oncogene, 21:7435-7451.
22. Ahrendt, S.A., Decker, P.A., Alawi, E.A., Zhu Yr, Y.R., Sanchez-Cespedes, M., Yang, S.C. et al. (2001). Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer, 92(6):1525-1530.
23. Johnson, L., Mercer, K., Greenbaum, D., Bronson, R.T., Crowley, D., Tuveson, D.A. et al. (2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature, 410(6832):1111-1116.
24. Lubet, R.A., Zhang, Z., Wiseman, R.W., and You, M. (2000). Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp Lung Res, 26(8):581-593.
25. Sekido, Y., Fong, K.W., and Minna, J.D. (1998). Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta, 1378:F21-F59.
26. Bode, A.M. and Dong, Z. (2005). Signal transduction pathways in cancer development and as targets for cancer prevention. Prog Nucleic Acid Res Mol Biol, 79:237-297.
27. Schuller, H.M. (2002). Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer, 2(6):455-463.
28. West, K.A., Brognard, J., Clark, A.S., Linnoila, I.R., Yang, X., Swain, S.M. et al. (2003). Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest, 111(1):81-90.
29. Heeschen, C., Jang, J.J., Weis, M., Pathak, A., Kaji, S., Hu, R.S. et al. (2001). Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med, 7(7):833-839.
30. Moraitis, D., Du, B., De Lorenzo, M.S., Boyle, J.O., Weksler, B.B., Cohen, E.G. et al. (2005). Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers:evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res, 65(2):664-670.
31. Belinsky, S.A. (2005). Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis, 26(9):1481-1487.
32. Cooper, C.S., Grover, P.L., and Sims, P. (1983). The metabolism and activation of benzo[a]pyrene. Prog Drug Metab, 7:295-396.
33. Conney, A.H. (1982). Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowes Memorial Lecture. Cancer Res, 42:4875-4917.
34. Hecht, S.S. (1998). Biochemistry, biology, and carcinogenicity of tobacco-specific Nnitrosamines. Chem Res Toxicol, 11:559-603.
35. Preussmann, R. and Stewart, B.W. (1984). N-Nitroso Carcinogens. In: C.E. Searle, (ed.) Chemical Carcinogens, Second Edition, ACS Monograph 182. Washington, DC:American Chemical Society, 643-828.
36. Stepanov, I. and Hecht, S.S. (2005). Tobacco-specific nitrosamines and their Nglucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiol Biomarkers & Prev, 14:885-891.
37. International Agency for Research on Cancer (1994). Some Industrial Chemicals. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon, FR: IARC, 73-159.
38. Zhang, S., Villalta, P.W., Wang, M., and Hecht, S.S. (2007). Detection and quantitation of acrolein-derived 1,N2-propanodeoxyguanosine adducts in human lung by liquid chromatography-electrospray ionization-tandem mass spectrometry. Chem Res Toxicol, 20:565-571.
39. Chen, L., Wang, M., Villalta, P.W., Luo, X., Feuer, R., Jensen, J. et al. (2007). Quantitation of an acetaldehyde adduct in human leukocyte DNA and the effect of smoking cessation. Chem Res Toxicol, 20:108-113.
40. Kadlubar, F.F. and Beland, F.A. (1985). Chemical properties of ultimate carcinogenic metabolites of arylamines and arylamides. In: R.G. Harvey, (ed.) Polycyclic Hydrocarbons and Carcinogenesis. Washington, D.C.: American Chemical Society, 341-371.
41. Szeliga, J. and Dipple, A. (1998). DNA adduct formation by polycyclic aromatic hydrocarbon dihydrodiol epoxides. Chem Res Toxicol, 11:1-11.
42. Hecht, S.S. (2008). Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol, 21:160-171.
43. Zhao, C., Tyndyk, M., Eide, I., and Hemminki, K. (1999). Endogenous and background DNA adducts by methylating and 2- hydroxyethylating agents. Mutat Res, 424(1-2):117-125.
44. Singh, R., Kaur, B., and Farmer, P.B. (2005). Detection of DNA damage derived from a direct acting ethylating agent present in cigarette smoke by use of liquid chromatography-tandem mass spectrometry. Chem Res Toxicol, 18(2):249-256.
45. Zhang, S., Villalta, P.W., Wang, M., and Hecht, S.S. (2006). Analysis of crotonaldehydeand acetaldehyde-derived 1,N2-propanodeoxyguanosine adducts in DNA from human tissues using liquid chromatography-electrsopray ionization-tandem mass spectrometry. Chem Res Toxicol, 19:1386-1392.
46. Boysen, G. and Hecht, S.S. (2003). Analysis of DNA and protein adducts of benzo[a]pyrene in human tissues using structure-specific methods. Mutation Res, 543:17-30.
47. Beland, F.A., Churchwell, M.I., Von Tungeln, L.S., Chen, S., Fu, P.P., Culp, S.J. et al. (2005). High-performance liquid chromatography electrospray ionization tandem mass spectrometry for the detection and quantitation of benzo[a]pyrene-DNA adducts. Chem Res Toxicol, 18(8):1306-1315.
48. Hoffmann, D., Schmeltz, I., Hecht, S.S., and Wynder, E.L. (1978). Tobacco carcinogenesis. In: H. Gelboin, P.O.P. Ts'o, (eds) Polycyclic Hydrocarbons and Cancer. New York: Academic Press, 85-117.
49. Deutsch-Wenzel, R., Brune, H., and Grimmer, G. (1983). Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. J Natl Cancer Inst, 71:539-544.
50. Phillips, D.H. (2002). Smoking-related DNA and protein adducts in human tissues. Carcinogenesis, 23(12):1979-2004.
51. Liu, Z., Muehlbauer, K.R., Schmeiser, H.H., Hergenhahn, M., Belharazem, D., and Hollstein, M.C. (2005). p53 Mutations in benzo[a]pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res, 65(7):2583-2587.
52. Belinsky, S.A., Foley, J.F., White, C.M., Anderson, M.W., and Maronpot, R.R. (1990). Dose-response relationship between O6-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone. Cancer Res, 50:3772-3780.
53. Foiles, P.G., Akerkar, S.A., Carmella, S.G., Kagan, M., Stoner, G.D., Resau, J.H. et al. (1991). Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers. Chem Res Toxicol, 4:364-368.
54. Schlöbe, D., Hölzle, D., Hatz, D., Von Meyer, L., Tricker, A.R., and Richter, E. (2008). 4-Hydroxy-1-(3-pyridyl)-1-butanone-releasing DNA adducts in lung, lower esophagus and cardia of sudden death victims. Toxicology, 245(1-2):154-161.
55. Hölzle, D., Schlöbe, D., Tricker, A.R., and Richter, E. (2007). Mass spectrometric analysis of 4-hydroxy-1-(3-pyridyl)-1-butanone-releasing DNA adducts in human lung. Toxicology, 232(3):277-285.
56. Hecht, S.S. (2002). Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis, 23:907-922.
57. Feng, Z., Hu, W., Hu, Y., and Tang, M.S. (2006). Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc Natl Acad Sci USA, 103(42):15404-15409.
58. International Agency for Research on Cancer (1986). Tobacco Smoking. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon, FR: IARC, 37-385.
59. Hoffmann, D. and Hecht, S.S. (1990). Advances in tobacco carcinogenesis. In: C.S. Cooper, P.L. Grover, (eds) Handbook of Experimental Pharmacology. Heidelberg:Springer-Verlag, 63-102.
60. International Agency for Research on Cancer (2007). Smokeless tobacco and tobaccospecific nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, v. 89. Lyon, FR: IARC, 548-553.
61. Prokopczyk, B., Leder, G., Trushin, N., Cunningham, A.J., Akerkar, S., Pittman, B. et al. (2005). 4-Hydroxy-1-(3-pyridyl)-1-butanone, an indicator for 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone-induced DNA damage, is not detected in human pancreatic tissue. Cancer Epidemiol Biomarkers Prev, 14(2):540-541.
62. Rivenson, A., Hoffmann, D., Prokopczyk, B., Amin, S., and Hecht, S.S. (1988). Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res, 48:6912-6917.
63. Prokopczyk, B., Hoffmann, D., Bologna, M., Cunningham, A.J., Trushin, N., Akerkar, S., et al. (2002). Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol, 15:677-685.
64. Skipper, P.L., Peng, X., SooHoo, C.K., and Tannenbaum, S.R. (1994). Protein adducts as biomarkers of human carcinogen exposure. Drug Metab Rev, 26:111-124.
65. Castelao, J.E., Yuan, J.M., Skipper, P.L., Tannenbaum, S.R., Gago-Dominguez, M., Crowder, J.S. et al. (2001). Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst, 93(7):538-545.
66. International Agency for Research on Cancer (1982). Some Industrial Chemicals and Dyestuffs. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon, FR: IARC, 93-148.
67. Zhang, L., Steinmaus, C., Eastmond, D.A., Xin, X.K., and Smith, M.T. (2008). Formaldehyde exposure and leukemia: a new meta-analysis and potential mechanisms. Mutat Res epub 15-July-2008.
68. Pryor, W.A., Stone, K., Zang, L.Y., and Bermudez, E. (1998). Fractionation of aqueous cigarette tar extracts: fractions that contain the tar radical cause DNA damage. Chem Res Toxicol, 11:441-448.
69. Dietrich, M., Block, G., Hudes, M., Morrow, J.D., Norkus, E.P., Traber, M.G. et al. (2002). Antioxidant supplementation decreases lipid peroxidation biomarker F(2)- isoprostanes in plasma of smokers. Cancer Epidemiol Biomarkers Prev, 11:7-13.
70. Hecht, S.S. (2005). Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new. Carcinogenesis, 26:1488-1492.
71. Lee, J.M., Yanagawa, J., Peebles, K.A., Sharma, S., Mao, J.T., and Dubinett, S.M. (2008). Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol, 66(3):208-217.
72. International Agency for Research on Cancer (1986). Tobacco Smoking. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon, FR: IARC, 37-375.
73. International Agency for Research on Cancer (2004). Tobacco Smoke and Involuntary Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, FR: IARC, 1012-1065.
74. Jongeneelen, F.J. (2001). Benchmark guideline for urinary 1-hydroxypyrene as biomarker of occupational exposure to polycyclic aromatic hydrocarbons. Ann Occup Hyg, 45:3-13.
75. Hecht, S.S., Carmella, S.G., Yoder, A., Chen, M., Li, Z., Le, C. et al. (2006). Comparison of polymorphisms in genes involved in polycyclic aromatic hydrocarbon metabolism with urinary phenanthrene metabolite ratios in smokers. Cancer Epidemiol Biomarkers & Prev, 15:1805-1811.
76. Hecht, S.S., Chen, M., Yagi, H., Jerina, D.M., and Carmella, S.G. (2003). r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthrene in human urine: a potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation. Cancer Epidemiol Biomarkers & Prev, 12:1501-1508.
77. Hatsukami, D.K., Benowitz, N.L., Rennard, S.I., Oncken, C., and Hecht, S.S. (2006). Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine and Tob Res, 8:600-622.
78. Hecht, S.S. (2003). Carcinogen derived biomarkers: applications in studies of human exposure to secondhand tobacco smoke. Tob Control, 13 (Suppl 1):i48-i56.
79. Hatsukami, D.K., Le, C.T., Zhang, Y., Joseph, A.M., Mooney, M.E., Carmella, S.G. et al. (2006). Toxicant exposure in cigarette reducers vs. light smokers. Cancer Epidemiol Biomarkers & Prev, 15:2355-2358.
80. Hecht, S.S., Murphy, S.E., Carmella, S.G., Zimmerman, C.L., Losey, L., Kramarczuk, I. et al. (2004). Effects of reduced cigarette smoking on uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst, 96:107-115.
81. Hecht, S.S., Murphy, S.E., Carmella, S.G., Li, S., Jensen, J., Le, C. et al. (2005). Similar uptake of lung carcinogens by smokers of regular, light, and ultra-light cigarettes. Cancer Epidemiol Biomarkers & Prev, 14:693-698.
82. Mendoza-Baumgart, M.I., Hecht, S.S., Zhang, Y., Murphy, S.E., Le, C., Jensen, J., and Hatsukami, D.K. (2007). Pilot study on lower nitrosamine smokeless tobacco products compared to medicinal nicotine. Nic Tob Res, 9:1309-1323.
83. Hatsukami, D.K., Ebbert, J.O., Anderson, A., Lin, H., Le, C., and Hecht, S.S. (2006). Smokeless tobacco brand switching: a means to reduce toxicant exposure?. Drug Alcohol Depend, 87:217-224.
84. Hatsukami, D.K., Lemmonds, C., Zhang, Y., Murphy, S.E., Le, C., Carmella, S.G. et al. (2004). Evaluation of carcinogen exposure in people who used 'reduced exposure' tobacco products. J Natl Cancer Inst, 96:844-852.
85. Hecht, S.S., Carmella, S.G., Le, K., Murphy, S.E., Boettcher, A.J., Le, C., et al. (2006). 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides in the urine of infants exposed to environmental tobacco smoke. Cancer Epidemiol Biomarkers & Prev, 15:988-992.
86. Stepanov, I., Upadhyaya, P., Feuer, R., Jensen, J., Hatsukami, D.K., and Hecht, S.S. (2008). Extensive metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers. Cancer Epidemiol Biomarkers & Prev, 17:1764-1773.
87. Scherer, G., Urban, M., Engl, J., Hagedorn, H.W., and Riedel, K. (2006). Influence of smoking charcoal filter tipped cigarettes on various biomarkers of exposure. Inhal Toxicol, 18(10):821-829.
88. Sapkota, A., Halden, R.U., Dominici, F., Groopman, J.D., and Buckley, T.J. (2006). Urinary biomarkers of 1,3-butadiene in environmental settings using liquid chromatography isotope dilution tandem mass spectrometry. Chem Biol Interact, 160(1):70-79.
89. Carmella, S.G., Chen, M., Zhang, Y., Zhang, S., Hatsukami, D.K., and Hecht, S.S. (2007). Quantitation of acrolein-derived 3-hydroxypropylmercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry: effects of cigarette smoking. Chem Res Toxicol, 20:986-990.
90. Scherer, G., Urban, M., Hagedorn, H.W., Feng, S., Kinser, R.D., Sarkar, M. et al. (2007). Determination of two mercapturic acids related to crotonaldehyde in human urine: influence of smoking. Hum Exp Toxicol, 26(1):37-47.
91. Scherer, G., Engl, J., Urban, M., Gilch, G., Janket, D., and Riedel, K. (2007). Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul Toxicol Pharmacol, 47(2):171-183.
92. Calafat, A.M., Barr, D.B., Pirkle, J.L., and Ashley, D.L. (1999). Reference range concentrations of N-acetyl-S-(2-hydroxyethyl)-L-cysteine, a common metabolite of several volatile organic compounds, in the urine of adults in the United States. J Expo Anal Environ Epidemiol, 9(4):336-342.
93. International Agency for Research on Cancer (2004). Tobacco Smoke and Involuntary Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, FR: IARC, 33-1187.
94. International Agency for Research on Cancer (2008). 1,3-Butadiene, Ethylene Oxide and Vinyl Halides (Vinyl Fluoride, Vinyl Chloride, and Vinyl Bromide). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, FR: IARC, 45-184.
95. Kensler, C.J. and Battista, S.P (1963). Components of cigarette smoke with ciliarydepressant activity. Their selective removal by filters containing activated charcoal granules. N Engl J Med, 269:1161-1166.
96. International Agency for Research on Cancer (1995). Dry cleaning, some chlorinated solvents and other industrial chemicals. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, FR: IARC, 373-391.
97. Bechtold, W.E., Strunk, M.R., Chang, I.Y., Ward, J.B. Jr., and Henderson, R.F. (1994). Species differences in urinary butadiene metabolites: comparisons of metabolite ratios between mice, rats, and humans. Toxicol Appl Pharmacol, 127(1):44-49.
98. Fustinoni, S., Soleo, L., Warholm, M., Begemann, P., Rannug, A., Neumann, H.G. et al. (2002). Influence of metabolic genotypes on biomarkers of exposure to 1,3- butadiene in humans. Cancer Epidemiol Biomarkers Prev, 11(10 Pt 1):1082-1090.
99. van Sittert, N.J., Megens, H.J., Watson, W.P., and Boogaard, P.J. (2000). Biomarkers of exposure to 1,3-butadiene as a basis for cancer risk assessment. Toxicol Sci, 56(1):189-202.
100. Boogaard, P.J., van Sittert, N.J., and Megens, H.J. (2001). Urinary metabolites and haemoglobin adducts as biomarkers of exposure to 1,3-butadiene: a basis for 1,3- butadiene cancer risk assessment. Chem Biol Interact, 135-136:695-701.
101. Urban, M., Gilch, G., Schepers, G., van Miert, E., and Scherer, G. (2003). Determination of the major mercapturic acids of 1,3-butadiene in human and rat urine using liquid chromatography with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 796(1):131-140.
102. Fustinoni, S., Perbellini, L., Soleo, L., Manno, M., and Foa, V. (2004). Biological monitoring in occupational exposure to low levels of 1,3-butadiene. Toxicol Lett, 149(1-3):353-360.
103. McDonald, J.D., Bechtold, W.E., Krone, J.R., Blackwell, W.B., Kracko, D.A., and Henderson, R.F. (2004). Analysis of butadiene urinary metabolites by liquid chromatography-triple quadrupole mass spectrometry. J Anal Toxicol, 28(3):168-173.
104. Albertini, R.J., Sram, R.J., Vacek, P.M., Lynch, J., Wright, M., Nicklas, J.A. et al. (2001). Biomarkers for assessing occupational exposures to 1,3-butadiene. Chem Biol Interact, 135-136:429-453.
105. Hayes, R.B., Zhang, L., Yin, S., Swenberg, J.A., Xi, L., Wiencke, J. et al. (2000). Genotoxic markers among butadiene polymer workers in China. Carcinogenesis, 21(1):55-62.
106. Albertini, R.J., Sram, R.J., Vacek, P.M., Lynch, J., Nicklas, J.A., van Sittert, N.J. et al. (2003). Biomarkers in Czech workers exposed to 1,3-butadiene: a transitional epidemiologic study. Res. Rep Health Eff Inst, 116:1-141.
107. Sarkar, M., Kapur, S., Frost-Pineda, K., Feng, S., Wang, J., Liang, Q. et al. (2008). Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies. Nicotine Tob Res, 10(12):1761-1772.
108. Mascher, D.G., Mascher, H.J., Scherer, G., and Schmid, E.R. (2001). Highperformance liquid chromatographic-tandem mass spectrometric determination of 3- hydroxypropylmercapturic acid in human urine. J Chromatogr B Biomed Sci Appl, 750(1):163-169.
109. Mendes, P., Kapur, S., Wang, J., Feng, S., and Roethig, H. (2008). A randomized, controlled exposure study in adult smokers of full flavor Marlboro cigarettes switching to Marlboro Lights or Marlboro Ultra Lights cigarettes. Regul Toxicol Pharmacol, 51(3):295-305.
110. Roethig, H.J., Feng, S., Liang, Q., Liu, J., Rees, W.A., and Zedler, B.K. (2008). A 12- month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J Clin Pharmacol, 48(5):580-591.
111. Qu, Q., Melikian, A.A., Li, G., Shore, R., Chen, L., Cohen, B. et al. (2000). Validation of biomarkers in humans exposed to benzene: urine metabolites. Am J Ind Med, 37(5):522-531.
112. Feng, S., Roethig, H.J., Liang, Q., Kinser, R., Jin, Y., Scherer, G. et al. (2006). Evaluation of urinary 1-hydroxypyrene, S-phenylmercapturic acid, trans,trans-muconic acid, 3-methyladenine, 3-ethyladenine, 8-hydroxy-2'-deoxyguanosine and thioethers as biomarkers of exposure to cigarette smoke. Biomarkers, 11(1):28-52.
113. Kim, S., Vermeulen, R., Waidyanatha, S., Johnson, B.A., Lan, Q., Rothman, N. et al. (2006). Using urinary biomarkers to elucidate dose-related patterns of human benzene metabolism. Carcinogenesis, 27(4):772-781.
114. Qu, Q., Cohen, B.S., Shore, R., Chen, L.C., Li, G., Jin, X. et al. (2003). Benzene exposure measurement in shoe and glue manufacturing: a study to validate biomarkers. Appl Occup Environ Hyg, 18(12):988-998.
115. van Sittert, N.J., Boogaard, P.J., and Beulink, G.D. (1993). Application of the urinary Sphenylmercapturic acid test as a biomarker for low levels of exposure to benzene in industry. Br J Ind Med, 50(5):460-469.
116. Barbieri, A., Sabatini, L., Accorsi, A., Roda, A., and Violante, F.S. (2004). Simultaneous determination of t,t-muconic, S-phenylmercapturic and S-benzylmercapturic acids in urine by a rapid and sensitive liquid chromatography/electrospray tandem mass spectrometry method. Rapid Commun Mass Spectrom, 18(17):1983-1988.
117. Maestri, L., Negri, S., Ferrari, M., Ghittori, S., and Imbriani, M. (2005). Determination of urinary S-phenylmercapturic acid, a specific metabolite of benzene, by liquid chromatography/single quadrupole mass spectrometry. Rapid Commun Mass Spectrom, 19(9):1139-1144.
118. Lin, L.C., Shih, J.F., Shih, T.S., Li, Y.J., and Liao, P.C. (2004). An electrospray ionization tandem mass spectrometry based system with an online dual-loop cleanup device for simultaneous quantitation of urinary benzene exposure biomarkers trans,trans-muconic acid and S-phenylmercapturic acid. Rapid Commun Mass Spectrom, 18(22):2743-2752.
119. Lin, L.C., Tyan, Y.C., Shih, T.S., Chang, Y.C., and Liao, P.C. (2004). Development and validation of an isotope-dilution electrospray ionization tandem mass spectrometry method with an on-line sample clean-up device for the quantitative analysis of the benzene exposure biomarker S-phenylmercapturic acid in human urine. Rapid Commun Mass Spectrom, 18(12):1310-1316.
120. Schettgen, T., Musiol, A., Alt, A., and Kraus, T. (2008). Fast determination of urinary S-phenylmercapturic acid (S-PMA) and S-benzylmercapturic acid (S-BMA) by columnswitching liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 863(2):283-292.
121. Sabatini, L., Barbieri, A., Indiveri, P., Mattioli, S., and Violante, F.S. (2008). Validation of an HPLC-MS/MS method for the simultaneous determination of phenylmercapturic acid, benzylmercapturic acid and o-methylbenzyl mercapturic acid in urine as biomarkers of exposure to benzene, toluene and xylenes. J Chromatogr B Analyt Technol Biomed Life Sci, 863(1):115-122.
122. Popp, W., Vahrenholz, C., Przygoda, H., Brauksiepe, A., Goch, S., Muller, G. et al. (1994). DNA-protein cross-links and sister chromatid exchange frequencies in lymphocytes and hydroxyethyl mercapturic acid in urine of ethylene oxide-exposed hospital workers. Int Arch Occup Environ Health, 66(5):325-332.
123. Barr, D.B. and Ashley, D.L. (1998). A rapid, sensitive method for the quantitation of N-acetyl-S-(2-hydroxyethyl)-L-cysteine in human urine using isotope-dilution HPLC-MSMS. J Anal Toxicol, 22(2):96-104.
124. De Bont, R. and van Larebeke, N. (2004). Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis, 19(3):169-185.
125. Singh, R. and Farmer, P.B. (2006). Liquid chromatography-electrospray ionizationmass spectrometry: the future of DNA adduct detection. Carcinogenesis, 27(2):178-196.
126. Poirier, M.C., Santella, R.M., and Weston, A. (2000). Carcinogen macromolecular adducts and their measurement. Carcinogenesis, 21(3):353-359.
127. Kriek, E., Rojas, M., Alexandrov, K., and Bartsch, H. (1998). Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk. Mutat Res, 400:215-231.
128. Wild, C.P. and Pisani, P. (1998). Carcinogen DNA and protein adducts as biomarkers of human exposure in environmental cancer epidemiology. Cancer Detection and Prevention, 22:273-283.
129. Arif, J.M., Dresler, C., Clapper, M.L., Gairola, C.G., Srinivasan, C., Lubet, R.A. et al. (2006). Lung DNA adducts detected in human smokers are unrelated to typical polyaromatic carcinogens. Chem Res Toxicol, 19(2):295-299.
130. International Agency for Research on Cancer (2004). Tobacco Smoke and Involuntary Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, FR: IARC, 35-102.
131. Veglia, F., Matullo, G., and Vineis, P. (2003). Bulky DNA adducts and risk of cancer: a meta-analysis. Cancer Epidemiol Biomarkers & Prev, 12(2):157-160.
132. Golkar, S.O., Ehrenberg, L., Segerback, D., and Hallstrom, I. (1976). Evaluation of genetic risks of alkyating agents II. Haemoglobin as a dose monitor. Mutat Res, 34:1-10.
133. Ehrenberg, L. and Osterman-Golkar, S. (1980). Alkylation of macromolecules for detecting mutagenic agents. Teratogenesis Carcinog Mutagen, 1:105-127.
134. Skipper, P.L. and Tannenbaum, S.R. (1990). Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis, 11:507-518.
135. Maclure, M., Bryant, M.S., Skipper, P.L., and Tannenbaum, S.R. (1990). Decline of the hemoglobin adduct of 4-minobiphenyl during withdrawal from smoking. Cancer Res, 50:181-184.
136. Bergmark, E. (1997). Hemoglobin adducts of acrylamide and acrylonitrile in laboratory workers, smokers and nonsmokers. Chem Res Toxicol, 10:78-84.
137. Fennell, T.R., MacNeela, J.P., Morris, R.W., Watson, M., Thompson, C.L., and Bell, D.A. (2000). Hemoglobin adducts from acrylonitrile and ethylene oxide in cigarette smokers: effects of glutathione S-transferase T1-null and M1-null genotypes. Cancer Epidemiol Biomarkers & Prev, 9(7):705-712.
138. Carmella, S.G., Chen, M., Villalta, P.W., Gurney, J.G., Hatsukami, D.K., and Hecht, S.S. (2002). Ethylation and methylation of hemoglobin in smokers and non-smokers. Carcinogenesis, 23(11):1903-1910.
139. Wang, M., Cheng, G., Villalta, P.W., and Hecht, S.S. (2007). Development of liquid chromatography electrospray ionization tandem mass spectrometry methods for analysis of DNA adducts of formaldehyde and their application to rats treated with Nnitrosodimethylamine or 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Chem Res Toxicol, 20(8):1141-1148.
140. Chen, L., Wang, M., Villalta, P.W., and Hecht, S.S. (2007). Liquid chromatographyelectrospray ionization tandem mass spectrometry analysis of 7-ethylguanine in human liver DNA. Chem Res Toxicol, 20(10):1498-1502.
141. Morrow, J.D., Frei, B., Longmire, A.W., Gaziano, J.M., Lynch, S.M., Shyr, Y. et al. (1995). Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. N Engl J Med, 332:1198-1203.
142. Murphey, L.J., Williams, M.K., Sanchez, S.C., Byrne, L.M., Csiki, I., Oates, J.A. et al. (2004). Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem, 334(2):266-275.
143. Burns, D.M., Dybing, E., Gray, N., Hecht, S., Anderson, C., Sanner, T. et al. (2008). Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization. TobReg proposal. Tob Control, 17(2):132-141.
144. Church, T.R., Anderson, K.E., Caporaso, N.E., Geisser, M.S., Le, C., Zhang, Y., et al. (2009). A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol, Biomarkers, & Prev 18:260-266.
145. Boffetta, P., Clark, S., Shen, M., Gislefoss, R., Peto, R., and Andersen, A. (2006). Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev, 15(6):1184-1188.
146. Yuan, Y.-M., Koh, W.-P., Murphy, S.E., Fan, Y., Wang, R., Carmella, S.G. et al. (2009). Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res., 69:2990-2995.